Special Issue "Advances in PET/CT Imaging for Breast Cancer Patients and Beyond"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".

Deadline for manuscript submissions: 25 May 2023 | Viewed by 1802

Special Issue Editors

1. Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France
2. Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France
Interests: PET/CT imaging; new tracers; breast cancer; prognostic/predictive biomarkers; precision medicine
Department of Radiology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA
Interests: artificial intelligence; radiomics; immunotherapy
Special Issues, Collections and Topics in MDPI journals
1. Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.
2. LTSI (Laboratoire Traitement du Signal et de l'Image), Université de Rennes 1, 35042 Rennes, France
Interests: medical imaging; nuclear medicine; lobular breast cancer; brain metastases

Special Issue Information

Dear Colleagues,

Over the last decade, molecular imaging has remarkably improved the management of patients with breast cancer. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is now a cornerstone for in vivo characterization and measurement of biologic processes, with several clinical applications, such as staging and assessment of treatment response. Moreover, innovative PET radiotracers present novel clinical opportunities, such as the selection of patients for endocrine therapy, anti-HER2 therapy, and immunotherapy. For patients with metastatic breast cancer, 18F-fluoroestradiol (FES) is a promising tracer that can be used for a whole-body assessment of estrogen receptor status. The fibroblast activation protein inhibitor (FAPI), labeled with Gallium-68 or Fluor-18, is also under investigation, with encouraging results. Thus,  several research teams have recently studied  FAPIs’ potential to compete with or even outperform FDG in a number of clinical indications, including diagnosis/staging, treatment response assessment, radiotherapy planning, and theranostics. For this Special Issue, we encourage the submission of papers considering innovative approaches using PET/CT imaging to guide the management of patients with a diagnosis of breast cancer.

Dr. Romain David Seban
Dr. Laurent Dercle
Dr. Antoine Girard
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • PET/CT imaging
  • fluorodeoxyglucose (FDG)
  • fluoroestradiol (FES)
  • tracers targeting fibroblast activation protein inhibitors (FAPI)

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

Editorial
Advances in PET/CT Imaging for Breast Cancer Patients and Beyond
J. Clin. Med. 2023, 12(2), 651; https://doi.org/10.3390/jcm12020651 - 13 Jan 2023
Viewed by 685
Abstract
Breast cancer is the most common cancer in women around the world and the fifth leading cause of cancer-related death [...] Full article
(This article belongs to the Special Issue Advances in PET/CT Imaging for Breast Cancer Patients and Beyond)

Review

Jump to: Editorial

Review
State of the Art in 2022 PET/CT in Breast Cancer: A Review
J. Clin. Med. 2023, 12(3), 968; https://doi.org/10.3390/jcm12030968 - 27 Jan 2023
Viewed by 605
Abstract
Molecular imaging with positron emission tomography is a powerful and well-established tool in breast cancer management. In this review, we aim to address the current place of the main PET radiopharmaceuticals in breast cancer care and offer perspectives on potential future radiopharmaceutical and [...] Read more.
Molecular imaging with positron emission tomography is a powerful and well-established tool in breast cancer management. In this review, we aim to address the current place of the main PET radiopharmaceuticals in breast cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of 18F-fluorodeoxyglucose positron emission tomography in the clinical management of breast cancer patients, especially during staging; detection of recurrence and evaluation of treatment response; the role of 16α-18Ffluoro-17β-oestradiol positron emission tomography in oestrogen receptors positive breast cancer; the promising radiopharmaceuticals, such as 89Zr-trastuzumab and 68Ga- or 18F-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence. Full article
(This article belongs to the Special Issue Advances in PET/CT Imaging for Breast Cancer Patients and Beyond)
Show Figures

Figure 1

Back to TopTop